Avalyn Pharma Inc.
AVLN
$30.71
$1.735.97%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -26.87M | -17.50M | |||
| Total Depreciation and Amortization | 63.00K | 10.00K | |||
| Total Amortization of Deferred Charges | 5.00K | -- | |||
| Total Other Non-Cash Items | 1.07M | -15.00K | |||
| Change in Net Operating Assets | -4.16M | -1.77M | |||
| Cash from Operations | -29.89M | -19.28M | |||
| Capital Expenditure | -318.00K | -8.00K | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 55.34M | 24.13M | |||
| Cash from Investing | 55.02M | 24.12M | |||
| Total Debt Issued | 15.00M | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 25.00K | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -163.00K | -- | |||
| Cash from Financing | 14.86M | -- | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 40.00M | 4.84M | |||